secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001559053-22-000046
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena Q3 2022 net loss $45.8M vs income $109.2M y/y; cash $497M; cuts FY22 net cash burn guidance to $108-120M
--------------------------------------------------------------------------------

- Net loss $45.8M ($0.97 per share) vs net income $109.2M ($2.13 diluted EPS) in Q3 2021.
- Total revenue $1.5M vs $139.2M y/y, primarily due to prior year BMS and Novo Nordisk milestones.
- Cash and restricted cash $497.0M; no debt; shares outstanding ~48.4M as of Oct 26.
- Updated FY2022 net cash burn guidance $108-120M (down from $120-132M); year-end cash ~$522M.
- R&D expenses $39.9M in Q3 2022 vs $18.0M y/y, driven by manufacturing and clinical costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905322000046/0001559053-22-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905322000046/prta-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001559053-22-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer